Article

Pharmaceutical Executive

Pharmaceutical Executive

Pharmaceutical Executive-04-01-2013
Volume0
Issue 0

PE, April 2013 Cover Image

S

Cover

Articles in this issue
i8_t-810226-1408541752788.jpg
Country Report: Belgium
On-Market Pricing Strategies
line-810217-1408541777966.gif
Is National Drug Pricing Freedom in Europe Nearing its Expiry Date?
i3_t-810227-1408541750193.jpg
Evidence-Based Marketing: From Rise to Stall—and Ultimate Triumph
i1-810216-1408541781420.jpg
PE, April 2013 Cover Image
Pfizer's Quality by Design Approach to Trial Management

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million
August 24th 2025

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million

Don Tracy, Associate Editor
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 24th 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Stock.adobe.com
August 24th 2025

Lighthouse Pharmaceuticals Awarded $49.2 Million Grant from NIA to Advance Phase 2 study of LHP588

Nicholas Jacobus
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 24th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
© WESTOCK - © WESTOCK - stock.adobe.com
August 24th 2025

Supreme Court Upholds NIH Funding Cuts Affecting DEI in Clinical Research

Andy Studna
XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction
August 24th 2025

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction

Don Tracy, Associate Editor